Company profile: Serimmune
1.1 - Company Overview
Company description
- Provider of antibody repertoire profiling and immune analytics via the Serum Epitope Repertoire Analysis (SERA) platform to identify disease-specific antigens and epitopes in a single assay; immune profiling with high-resolution epitope mapping and immune status reports; biomarker discovery across infectious diseases, cancer, and autoimmunity; Titan panel covering 50+ infectious diseases; and population serosurveillance.
Products and services
- Biomarker Discovery Services: Architects SERA-enabled assays to identify validated and novel biomarkers across infectious diseases, cancer, and autoimmunity
- Immune Profiling Services: Delivers peptide-display-based analyses of IgG antibodies using a bacterial peptide display library, producing high-resolution epitope mapping and immune status reports from submitted samples
- Serum Epitope Repertoire Analysis (SERA) Platform: Engineers a single-assay technology that profiles antibody repertoires to identify disease-specific antigens and epitopes across many diseases for comprehensive serological characterization
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Serimmune
Amira Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule pharmaceutical research focused on the discovery and early development of new drugs to treat inflammatory disease, leveraging unparalleled insights into bioactive lipid pathways and complex signaling processes controlling conditions including asthma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amira Pharmaceuticals company profile →
Taligen Therapeutics
HQ: United States
Website
- Description: Provider of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases, with lead candidates including monoclonal antibodies and recombinant fusion proteins targeting key factors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Taligen Therapeutics company profile →
Novellus Therapeutics
HQ: United States
Website
- Description: Provider of engineered cellular medicines using non-immunogenic mRNA molecules to safely and efficiently reprogram and gene-edit cells, engineering precision medicines for patient segments via a technology toolbox spanning in vivo and ex vivo applications, including allogeneic and autologous approaches.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novellus Therapeutics company profile →
Medsenic
HQ: France
Website
- Description: Provider of drug development and manufacturing focused on drugs for the treatment of autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medsenic company profile →
Graviton
HQ: United States
Website
- Description: Provider of clinical-stage biotech therapies, developing selective ROCK2 inhibitors for fibrotic, autoimmune and CNS diseases; a C6 monoclonal antibody for neurodegenerative diseases; and DYRK inhibitors for diabetes, neurological disorders and cancers. Conducts clinical trials and partners with Ovid Therapeutics and Sino Biopharmaceutical for development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Graviton company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Serimmune
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Serimmune
2.2 - Growth funds investing in similar companies to Serimmune
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Serimmune
4.2 - Public trading comparable groups for Serimmune
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →